In today’s episode, we welcome expert Oncologist Dr. Lori Wirth and expert Pathologist Dr. Thomas Giordano to discuss the challenges they have encountered and strategies that they have implemented to improve multidisciplinary collaboration in the management of patients with thyroid cancer and continued integration of precision medicine approaches.

References

1. Kilagat K, Griffin MJ, Baik F, et al. Thyroid Care Collaborative: an electronic health record facilitating multidisciplinary management of thyroid cancer. Int J Endo Oncol 2018;5(1):IJE03

Target Audience:

Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.

Learning Objective:

1. Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
2. Discuss “precision medicine” and new technologies, including “liquid biopsy”
3. Review the organisation of care and strategies for more efficient care delivery

These learning objectives are for the podcast series. This episode focuses on the third objective.

By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment.

Funding Information:

This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.

Staff Disclosures:

Dr Lori Wirth

Advisory Board - Bayer Healthcare, Coherus, Eli Lilly, Eisai, Exelixis, PDS Biotechnology Corp

Consultant - Curie Therapeutics, Morphic Therapeutics

Dr. Thomas Giordano

No relevant disclosures to declare